| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
By directly binding to HdmX, CTX1 inhibits the development of the p53-HdmX complex and quickly induces p53 in a way that is independent of DNA damage [1].
|
|---|---|
| ln Vivo |
In an AML model system, mice treated with CTX1 (30 mg/kg; intraperitoneal injection; five days per week; for three weeks) have a markedly higher survival rate [1]. Both by itself and in conjunction with nutlin-3, CTX1 exhibited strong anticancer activity[1].
|
| References |
| Molecular Formula |
C14H10N4
|
|---|---|
| Molecular Weight |
234.26
|
| Exact Mass |
234.09
|
| CAS # |
501935-96-2
|
| PubChem CID |
435038
|
| Appearance |
Reddish brown to red solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
582.5±30.0 °C at 760 mmHg
|
| Flash Point |
306.1±24.6 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.797
|
| LogP |
0.54
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
18
|
| Complexity |
334
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PUMGFEMNXBLDKD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H10N4/c15-7-12-10-3-1-8(16)5-13(10)18-14-6-9(17)2-4-11(12)14/h1-6H,16-17H2
|
| Chemical Name |
3,6-diaminoacridine-9-carbonitrile
|
| Synonyms |
CTX1 CTX 1 CTX-1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~53.36 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.25 mg/mL (5.34 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (5.34 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2688 mL | 21.3438 mL | 42.6876 mL | |
| 5 mM | 0.8538 mL | 4.2688 mL | 8.5375 mL | |
| 10 mM | 0.4269 mL | 2.1344 mL | 4.2688 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02053753 | COMPLETEDWITH RESULTS | Drug: Denosumab CP4 Drug: Denosumab CP2 |
Healthy Volunteer | Amgen | 2014-02 | Phase 1 |
| NCT06395883 | NOT YET RECRUITING | Drug: Glucocorticoid Effect | Inflammatory Rheumatism Osteoporosis Osteoporosis, Steroid Induced |
Diakonhjemmet Hospital | 2024-09 | |
| NCT04259242 | COMPLETED | Procedure: SRP | Periodontitis | Postgraduate Institute of Dental Sciences Rohtak | 2020-01-01 | Not Applicable |
| NCT04213105 | UNKNOWN STATUS | Drug: QL1206 Drug: Prolia® |
Healthy People | Qilu Pharmaceutical Co., Ltd. | 2019-10-31 | Phase 1 |
| NCT04198636 | UNKNOWN STATUS | Drug: LY01011 Drug: Xgeva 120 MG in 1.7 ML Injection |
Healthy Adults | Luye Pharma Group Ltd. | 2019-12-16 | Phase 1 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
